2024
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patients
2018
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Annals Of Hematology 2018, 98: 339-350. PMID: 30413901, DOI: 10.1007/s00277-018-3539-7.Peer-Reviewed Original ResearchConceptsIntermediate-risk myelodysplastic syndromesIron chelation therapyAcute myeloid leukemiaOverall survivalMyelodysplastic syndromeIron overloadSystematic reviewChelation therapyWorld Health Organization Clinical Trials RegistryInternational Prognostic Scoring System lowLower-risk myelodysplastic syndromesClinical Trials RegistryRisk of progressionRisk of mortalityOverall low riskHazard ratio estimatesRandom-effects modelNonrandomized trialsTrials RegistryCochrane DatabaseDisease progressionBias riskMyeloid leukemiaObservational studyLower risk
2016
Decision-making and Management of Ulnar Polydactyly of the Newborn: Outcomes and Satisfaction
Samra S, Bourne D, Beckett J, Matthew M, Thomson JG. Decision-making and Management of Ulnar Polydactyly of the Newborn: Outcomes and Satisfaction. The Journal Of Hand Surgery (Asian-Pacific Volume) 2016, 21: 313-320. PMID: 27595947, DOI: 10.1142/s2424835516500272.Peer-Reviewed Original ResearchConceptsLocal anesthesiaSatisfaction scoresInitial treatment decisionsUlnar polydactylyParents of newbornsMonths of ageCongenital hand deformitiesType of deformityPost-axial polydactylySurgical complicationsNonrandomized trialsGeneral anesthesiaHand deformitiesMajority of parentsResidual deformityTreatment optionsImmediate excisionHand surgeonsTreatment decisionsSuture ligaturesOptimal managementDeformityExcisionAnesthesiaNewborns
2004
Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer
Nakabayashi M, Oh W. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Current Treatment Options In Oncology 2004, 5: 349-355. PMID: 15341673, DOI: 10.1007/s11864-004-0025-3.Peer-Reviewed Original ResearchConceptsHigh-risk localized prostate cancerLocalized prostate cancerLocally advanced prostate cancerHormone-refractory diseaseAdvanced prostate cancerProstate cancerAdjuvant chemotherapyLocal therapyTreatment of hormone-refractory prostate cancerHormone-refractory prostate cancerDefinitive local therapyDefinitive local treatmentImproved clinical benefitProspective randomized trialsRisk of recurrenceOptimal treatment strategyImproved survival ratesRandomized clinical trialsRadical prostatectomyChe-motherapySurvival benefitClinical benefitLocal treatmentChemotherapyNonrandomized trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply